Literature DB >> 32196558

Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function.

An-Sofie Schelpe1, Anastasis Petri2, Elien Roose1, Inge Pareyn1, Hans Deckmyn1, Simon F De Meyer1, James T B Crawley2, Karen Vanhoorelbeke1.   

Abstract

Plasma ADAMTS13 circulates in a folded conformation that is stabilized by an interaction between the central Spacer domain and the C-terminal CUB (complement components C1r and C1s, sea urchin protein Uegf, and bone morphogenetic protein-1) domains. Binding of ADAMTS13 to the VWF D4(-CK) domains or to certain activating murine monoclonal antibodies (mAbs) induces a structural change that extends ADAMTS13 into an open conformation that enhances its function. The objective was to characterize the mechanism by which conformational activation enhances ADAMTS13-mediated proteolysis of VWF. The activating effects of a novel anti-Spacer (3E4) and the anti-CUB1 (17G2) mAbs on the kinetics of proteolysis of VWF A2 domain fragments by ADAMTS13 were analyzed. mAb-induced conformational changes in ADAMTS13 were investigated by enzyme-linked immunosorbent assay. Both mAbs enhanced ADAMTS13 catalytic efficiency (kcat/Km) by ∼twofold (3E4: 2.0-fold; 17G2: 1.8-fold). Contrary to previous hypotheses, ADAMTS13 activation was not mediated through exposure of the Spacer or cysteine-rich domain exosites. Kinetic analyses revealed that mAb-induced conformational extension of ADAMTS13 enhances the proteolytic function of the metalloprotease domain (kcat), rather than augmenting substrate binding (Km). A conformational effect on the metalloprotease domain was further corroborated by the finding that incubation of ADAMTS13 with either mAb exposed a cryptic epitope in the metalloprotease domain that is normally concealed when ADAMTS13 is in a closed conformation. We show for the first time that the primary mechanism of mAb-induced conformational activation of ADAMTS13 is not a consequence of functional exosite exposure. Rather, our data are consistent with an allosteric activation mechanism on the metalloprotease domain that augments active site function.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32196558      PMCID: PMC7094026          DOI: 10.1182/bloodadvances.2019001375

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  16 in total

1.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

2.  Allosteric activation of ADAMTS13 by von Willebrand factor.

Authors:  Joshua Muia; Jian Zhu; Garima Gupta; Sandra L Haberichter; Kenneth D Friedman; Hendrik B Feys; Louis Deforche; Karen Vanhoorelbeke; Lisa A Westfield; Robyn Roth; Niraj Harish Tolia; John E Heuser; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

3.  Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor.

Authors:  Masashi Akiyama; Soichi Takeda; Koichi Kokame; Junichi Takagi; Toshiyuki Miyata
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-30       Impact factor: 11.205

4.  Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13.

Authors:  L Deforche; E Roose; A Vandenbulcke; N Vandeputte; H B Feys; T A Springer; L Z Mi; J Muia; J E Sadler; K Soejima; H Rottensteiner; H Deckmyn; S F De Meyer; K Vanhoorelbeke
Journal:  J Thromb Haemost       Date:  2015-10-20       Impact factor: 5.824

5.  An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.

Authors:  E Roose; A S Schelpe; B S Joly; M Peetermans; P Verhamme; J Voorberg; A Greinacher; H Deckmyn; S F De Meyer; P Coppo; A Veyradier; K Vanhoorelbeke
Journal:  J Thromb Haemost       Date:  2018-01-23       Impact factor: 5.824

6.  FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.

Authors:  Koichi Kokame; Yuko Nobe; Yoshihiro Kokubo; Akira Okayama; Toshiyuki Miyata
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

7.  Conformational activation of ADAMTS13.

Authors:  Kieron South; Brenda M Luken; James T B Crawley; Rebecca Phillips; Mari Thomas; Richard F Collins; Louis Deforche; Karen Vanhoorelbeke; David A Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

8.  Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor.

Authors:  Xiaohui Zhang; Kenneth Halvorsen; Cheng-Zhong Zhang; Wesley P Wong; Timothy A Springer
Journal:  Science       Date:  2009-06-05       Impact factor: 47.728

Review 9.  Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor.

Authors:  James T B Crawley; Rens de Groot; Yaozu Xiang; Brenda M Luken; David A Lane
Journal:  Blood       Date:  2011-06-29       Impact factor: 22.113

10.  A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor.

Authors:  Kieron South; Marta O Freitas; David A Lane
Journal:  J Biol Chem       Date:  2017-02-16       Impact factor: 5.157

View more
  7 in total

Review 1.  ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.

Authors:  Konstantine Halkidis; X Long Zheng
Journal:  J Thromb Haemost       Date:  2022-08-03       Impact factor: 16.036

2.  A human monoclonal antibody against the distal carboxyl terminus of ADAMTS-13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura.

Authors:  Konstantine Halkidis; Don L Siegel; X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-05-11       Impact factor: 16.036

3.  Generation and validation of small ADAMTS13 fragments for epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Kadri Kangro; Elien Roose; An-Sofie Schelpe; Edwige Tellier; Gilles Kaplanski; Jan Voorberg; Simon F De Meyer; Andres Männik; Karen Vanhoorelbeke
Journal:  Res Pract Thromb Haemost       Date:  2020-06-25

4.  ADAMTS proteases in cardiovascular physiology and disease.

Authors:  Salvatore Santamaria; Rens de Groot
Journal:  Open Biol       Date:  2020-12-23       Impact factor: 6.411

Review 5.  Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.

Authors:  Junxian Yang; Zhiwei Wu; Quan Long; Jiaqi Huang; Tiantian Hong; Wang Liu; Jiangguo Lin
Journal:  Front Immunol       Date:  2020-12-02       Impact factor: 7.561

6.  Crystal structure of ADAMTS13 CUB domains reveals their role in global latency.

Authors:  H J Kim; Y Xu; A Petri; K Vanhoorelbeke; J T B Crawley; J Emsley
Journal:  Sci Adv       Date:  2021-04-16       Impact factor: 14.136

7.  Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP.

Authors:  Laure De Waele; Alexandre Curie; Kadri Kangro; Edwige Tellier; Gilles Kaplanski; Andres Männik; Claudia Tersteeg; Bérangère S Joly; Paul Coppo; Agnès Veyradier; Simon F De Meyer; Elien Roose; Karen Vanhoorelbeke
Journal:  Blood Adv       Date:  2021-11-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.